1 RARS-T is characterised by a high rate of JAK2 V617F mutations [2] [3] [4] or the presence of mutations in exon 10 of MPL (myeloproliferative leukaemia). 5, 6 The existence of RARS-T as an entity independent from RARS and essential thrombocythemia (ET) was a matter of debate, as certain specialists favoured the hypothesis that RARS-T was a form of ET with 415% of ring sideroblasts in the bone marrow, whereas others thought that RARS-T is derived from RARS with secondary thrombocytosis developing through the acquisition of the JAK2 V617F mutation. We recently demonstrated that RARS-T differed from RARS and ET from a clinical, biological and prognostic point of view. 4 The presence of high rates of splicing factor 3B subunit 1 (SF3B1) mutations in RARS-T and the absence of these mutations in ET strengthened the hypothesis that RARS-T was a distinct entity. [7] [8] [9] However, the myeloproliferative features of RARS-T are not totally explained by JAK2 V617F and MPL W515L mutations, as these account for only 50% and 1% of RARS-T, respectively. The question remains about other causative mutations responsible for the myeloproliferative part of RARS-T. The challenge is the same in myeloproliferative neoplasms (MPN), as 50-60% of ET and primary myelofibrosis (PMF) do not present with any JAK2 or MPL mutations.
The recent discovery of a high rate of calreticulin (CALR) mutations in JAK2-non-mutated MPNs was a great step towards better understanding of the molecular pattern of these diseases. Mutations in exon 9 of CALR have been reported as mutually exclusive of JAK2 and MPL mutations, and found in 67-71% of ET and 56-88% of PMF with wild-type JAK2 or MPL.
10,11 These mutations are insertions or deletions leading to a frameshift responsible for modifying the C-terminal part of the protein. Following these modifications, the C-terminal part of the protein becomes positively charged and the reticulum targeting KDEL sequence is abrogated, which disturbs its cellular localisation.
Up to now, CALR mutations have only been explored in small RARS-T cohorts, with a mutation frequency ranging from 0 to 12.5%. 10, 11 The purpose of our study was to analyse the frequency of CALR mutations in a large RARS-T cohort in order to determine whether CALR mutations may also be responsible for thrombocytosis in this disease. We therefore analysed a large cohort of 95 RARS-T patients, with 29 RARS as the control.
According to the WHO 2008 classification, patients are diagnosed with RARS-T if they fulfil the following criteria: i) anaemia (haemoglobin level o125 g/l for females and o135 g/l for males) with erythroid dysplasia and 415% ring sideroblasts; ii) thrombocytosis with 4450 Â 10 9 platelets/l; iii) o5% blast cells in the bone marrow; iv) presence of large atypical megakaryocytes similar to those observed in BCR-ABL1-negative MPN; v) no secondary cause of ring sideroblasts; and vi) no karyotype abnormalities such as del(5q), t(3;3)(q21;q26) or inv(3)(q21q26).
1 One hundred and twenty -four samples including 95 RARS-T and 29 RARS from seven European centres in three European countries were collected and tested. This cohort has been published previously. 4, 9 For each patient, demographic (gender and age at diagnosis) and biological data (blood cell count, bone marrow exploration, ring sideroblasts, karyotype and molecular explorations) were collected.
The SF3B1 mutations were analysed with a sensitive nextgeneration amplicon deep-sequencing assay (454 Life Sciences, Branford, CT, USA) with a median coverage of 500 reads. This approach was able to detect mutations with a sensitivity below 1%. 9 The JAK2 V617F mutation was analysed by allele-specific real-time PCR to estimate the allele burden according to the method published by Lippert et al. 12 with a sensitivity of 1%. JAK2 exon 12 analysis was performed according to the method by Schnittger et al. 13 and the MPL W515 mutations were analysed by highresolution melting curve analyses followed by Sanger sequencing if positive, as previously published by Schnittger et al. 14 The CALR exon 9 mutations were screened by fragment analysis and Sanger sequencing according to the method by Klampfl et al. A total of 124 cases with 95 RARS-T and 29 RARS (including 62 males and 62 females) were recorded in the study, which is, to our best knowledge, the largest series of myelodysplastic syndromes with ring sideroblasts (MDS-RS) studied for CALR mutations. The median age at diagnosis was 74 years and 73 years for the RARS-T and RARS cohort, respectively (Table 1) . A karyotype was available in 112 cases (87 RARS-T and 25 RARS). Seventy-five (86.2%) RARS-T patients carried a normal karyotype, whereas 12 (13.8%) patients showed aberrant karyotypes. The rates in RARS-T and RARS patients were comparable.
An SF3B1 mutation was noted in 24 (82.7%) RARS and 83 (88.3%) RARS-T confirming that this mutation is highly represented in MDS-RS.
A JAK2 V617F mutation was noted in 47 of the 95 RARS-T patients (49.4%) but in no RARS patients. The JAK2 V617F allele burden was very heterogeneous with a median of 33.3% (range: 1-92%). No JAK2 exon 12 mutation (19 tested) was observed, whereas only one MPL W515L mutation was noted in a patient with RARS-T (88 tested; Table 1 and Figure 1) .
A CALR mutation was noted in only one (1%) RARS-T and one (3.4%) RARS patient. The CALR mutation found in the RARS-T patient was a 10-bp (1129-1138) deletion located in exon 9. Surprisingly, this patient also presented a JAK2 V617F mutation with a low allele burden (4%) and an SF3B1 mutation. The mutational status of this patient was confirmed by two independent laboratories on two different DNA samples. This patient is a 73-year-old women diagnosed in 2010. At diagnosis, her blood cell count revealed anaemia (haemoglobin 106 g/l) and a marked thrombocytosis (992 Â 10 9 platelets/l). She is currently under cytoreductive and antiplatelet treatment and her last blood count revealed a mild anaemia (haemoglobin 104 g/l) and a platelet count lowered to 600 Â 10 9 /l. Among the 29 RARS, we also identified a single case with a CALR mutation. This unique CALR-positive RARS case was a 70-year-old man who had thrombocytopenia and carried an SF3B1 mutation.
In the present study on JAK2 and MPL mutations, our results are in accordance with the usually reported prevalence of JAK2 V617F in half of RARS-T and the low frequency of MPL mutations. [2] [3] [4] [5] [6] Recent publications have reported a variable frequency of CALR mutations in MDS-RS: 0/6 to 3/24 in RARS-T, 3/27 in RARS and 0/3 in refractory cytopenia with multilineage dysplasia and ring sideroblasts. 10, 11 However, these results were obtained in small series of patients, thus leading to potential biases. Of note, a high proportion (12.5%) of CALR mutations in RARS-T in one series of 24 patients contrasts with our results where only one positive case in 95 patients was noted. In particular, one of the three previously reported CALRpositive RARS-T cases did not harbour the SF3B1 mutation, a frequent hallmark of RARS-T. Moreover, in this series, the frequency of the SF3B1 mutation was much lower than in ours (66% vs 88%) suggesting that this CALR-positive SF3B1-negative RARS-T case could be MPN rather than RARS-T, owing to the difficulty of asserting the diagnosis in some cases. Finally, the low rate of CALR mutations in the present RARS-T series is similar (0-3%) to that reported in chronic myelomonocytic leukaemia, another MDS/MPN. 10, 11 Abbreviations: CALR, calreticulin; JAK2, Janus kinase 2; MPL, myeloproliferative leukaemia; SF3B1, splicing factor 3B subunit 1; RARS, refractory anaemia with ring sideroblasts; RARS-T, refractory anaemia with ring sideroblasts and marked thrombocytosis; WBC, white blood cells. , MPL and CALR mutations were observed in 88.3%, 49.4%, 1.1% and 1%, respectively. In RARS patients, SF3B1, JAK2
V617F
, MPL and CALR mutations were observed in 82.7%, 0%, 0% and 3.4%, respectively.
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Among the 29 RARS, we also identified a single case with a CALR mutation, which is consistent with a previous report.
11 Surprisingly, the CALR-positive RARS-T patient also carried the JAK2 V617F mutation, which is to date, the first double-mutant JAK2/ CALR ever described in RARS-T. Indeed, the CALR and JAK2 V617F mutations were described as mutually exclusive in the two recent studies of 42300 haematologic cancers. 10, 11 However, another group recently described a case of a JAK2/CALR double mutation in PMF, 15 which is in keeping with our results and proves that these mutations coexist in rare cases. One can hypothesise that this RARS-T patient with a JAK2/CALR mutation had two different clones. However, owing to absence of frozen progenitor cells, no clonogenic assay was feasible.
The two major types of CALR mutations are type 1 mutations (52 bp deletion; c.1192_1143del) and type 2 mutations (5 bp insertion; c.1154_1155insTTGTC). 10 The CARL mutation described in our RARS-T is a 10-bp deletion (1129-1138del), which is a rare type of CALR exon 9 mutation that shifts the reading frame in a similar way to all reported CALR mutations.
Finally, our study showed that CALR mutations are rare in MDS-RS and thus do not explain the myeloproliferative part of RARS-T. Approximately 40-50% of RARS-T are triple-negative for JAK2, MPL and CALR mutations, indicating that further research is required to explain the myeloproliferation in this rare MDS/MPN.
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